Trial Profile
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2022
Price :
$35
*
At a glance
- Drugs GSK 2330811 (Primary)
- Indications Diffuse scleroderma; Systemic scleroderma
- Focus Adverse reactions; Proof of concept
- Sponsors GlaxoSmithKline; GSK
- 18 May 2022 Insights from this study were published in the Rheumatology
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.
- 02 Mar 2020 Planned End Date changed from 29 Jun 2020 to 2 Jul 2020.